Quantcast

Latest Hemodialysis Stories

2014-08-26 12:29:08

New educational resources now make it even easier for facilities to implement and encourage ongoing compliance with Prevantics® products. ORANGEBURG, N.Y., Aug. 26, 2014 /PRNewswire/ -- PDI, leader in infection prevention products and solutions, continues to reinforce the importance of a complete infection prevention program for skin antisepsis. Prevantics(®) products are the first and only 3.15% Chlorhexidine Gluconate (w/v) and 70% Isopropyl Alcohol (v/v) formula which has been...

2014-08-25 08:27:42

Patients, nurses and nephrologists nominate their "Nurse Hero" in celebration of Nephrology Nurses Week LAWRENCE, Mass., Aug. 25, 2014 /PRNewswire/ -- NxStage® Medical, Inc., a leading manufacturer of innovative dialysis products, today launched the Nurse Hero Campaign a first-of-its-kind home hemodialysis nurse recognition that honors the dedication and compassion of the nephrology nursing community. Beginning today, patients, nephrologists and fellow nurses can nominate their...

2014-08-20 23:02:26

A common approach to treating kidney failure by removing waste products from the blood did not improve survival chances for people who suddenly developed the condition, in a new analysis led by experts at the University of Pittsburgh School of Medicine. Pittsburgh, PA (PRWEB) August 20, 2014 A common approach to treating kidney failure by removing waste products from the blood did not improve survival chances for people who suddenly developed the condition, in an analysis led by experts...

2014-08-18 16:28:18

Second Phase 3 Registrational Study Meets Primary and All Secondary Endpoints THOUSAND OAKS, Calif., Aug. 18, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that a second placebo-controlled Phase 3 study evaluating AMG 416 for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD), receiving hemodialysis, met its primary and all secondary endpoints. The primary endpoint was the proportion of patients with > 30 percent...

2014-08-14 20:22:56

RIVER EDGE, N.J., Aug. 14, 2014 /PRNewswire/ -- Nephros, Inc. (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for the treatment of chronic renal failure patients, announced today financial results for the three and six months ended June 30, 2014. Recent Highlights -- First commercial use of the Nephros on-line mid-dilution hemodiafiltration...

2014-08-14 16:27:40

Signs Business Collaboration in South Korea with Wonik Corporation BRIDGEWATER, N.J., Aug. 14, 2014 /PRNewswire/ -- CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal and infectious disease, today announced the U.S. Food and Drug Administration (FDA) has agreed with the design of our pivotal Phase III protocol for Neutrolin® in Hemodialysis patients, and the company...

2014-08-12 04:21:14

Four internationally renowned renal care specialists to assist Quanta as it prepares for the clinical introduction of its advanced haemodialysis system ALCESTER, England, August 12, 2014 /PRNewswire/ -- Quanta Fluid Solutions Ltd ("Quanta" or the "Company"), a pioneering developer of advanced haemodialysis systems, today announces it has appointed four leading renal experts to its newly established Medical Advisory Board. Prof. John Agar, Dr. Roger Greenwood, Dr. Clara Day and...

2014-08-07 04:21:45

ALCESTER, England, August 7, 2014 /PRNewswire/ -- Quanta Fluid Solutions Ltd ("Quanta" or the "Company"), a pioneering developer of advanced haemodialysis systems, today announces the appointment of Willem Baralt as Chief Financial Officer. Willem has almost twenty years of investment banking, executive management and private equity experience. Amongst his achievements, Willem was pivotal in the $1.6billion turnaround and public listing of FLAG Telecom and was...

2014-08-05 08:35:12

ATLANTA, Aug. 5, 2014 /PRNewswire/ --CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that it will participate in the upcoming 34(th) Annual Canaccord Genuity Growth Conference on Wednesday, August 13, 2014 at the InterContinental Boston Hotel. http://photos.prnewswire.com/prnvar/20140319/MM86518LOGO A live webcast of the Company's presentation is scheduled to begin at 8:00 a.m. ET and will...

2014-07-30 16:29:56

ATLANTA, July 30, 2014 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that its Board of Directors has approved a quarterly cash dividend for the third quarter 2014 of $0.03 per share of common stock outstanding. The quarterly cash dividend of $0.03 per share will be paid on September 19, 2014 to all common stockholders of record as of September 12, 2014. The ex-dividend date...


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.